Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Industry association · Netherlands
Declared costs: €50K+ a year · in the register since 2023
Industry association · Spain
Declared costs: €100K+ a year · in the register since 2015
Medicinal products for human use · A European Health Data Space · Revision of the EU legislation on medicines for children and rare diseases · Compulsory licensing of patents in crisis situations · Supplementary protection certificate for plant protection products. Recast
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Vereniging Innovatieve Geneesmiddelen · filed 26 Apr 2021 · source
The Vereniging Innovatieve Geneesmiddelen (VIG) considers the evaluation of the pharmaceutical legislation an opportunity to draw lessons from the COVID-19 pandemic and prepare for the future. To remain attractive for innovation and R&D while effectively responding to future challenges and threats.
Farmaindustria · filed 27 Apr 2021 · source
Farmaindustria considers it crucial to preserve the stability and predictability of the current European framework of incentives to attract investment and enable the pharmaceutical industry to continue to innovate in Europe, achieving better health outcomes.
Filed in Spanish · English published by the European Commission
Farmaindustria · filed 6 Nov 2023 · source
Farmaindustria (FI) supports the ultimate objective of the EC Proposal to improve the availability and access to medicines by promoting an innovative and competitive environment in the EU. We welcome the intention to prepare a regulatory framework for the future, maximising the use of fast-track procedures, optimising regulatory decision-making processes and reducing unnecessary red tape.
Filed in Spanish · English published by the European Commission
Vereniging Innovatieve Geneesmiddelen · filed 7 Nov 2023 · source
On behalf of the Association Innovative Medicines (VIG), the Dutch industry association of 44 innovative medicines manufacturers, our response to the proposed revision of the EU pharmaceutical legislation. The members of the VIG are active in the biopharmaceutical ecosystem of the Netherlands, which extends from academic institutions and hospitals to medicine developers and service companies.
Filed in Dutch · English published by the European Commission
Vereniging Innovatieve Geneesmiddelen · filed 7 Nov 2023 · source
On behalf of the Association Innovative Medicines (VIG), the Dutch industry association of 44 innovative medicines manufacturers, our response to the proposed revision of the EU pharmaceutical legislation. The members of the VIG are active in the biopharmaceutical ecosystem of the Netherlands, which extends from academic institutions and hospitals to medicine developers and service companies.
Filed in Dutch · English published by the European Commission
Farmaindustria · filed 27 Jan 2021 · source
Firstly, the Spanish National Pharmaceutical Industry Business Association (Farmaindustria) thanks the European Commission for opening the Inception Impact Assessment (IIA) on the forcing legislative proposal to create a European Health Data Space (EHDS). The necessary digital transformation of the health system has been highlighted during the recent COVID-19 crisis, with a strong boost to e-health solutions.
Filed in Spanish · English published by the European Commission
Vereniging Innovatieve Geneesmiddelen · filed 4 Feb 2021 · source
The Vereniging Innovatieve Geneesmiddelen (VIG) is positive towards the proposal of the European Commission to establish a European Health Data Space (EHDS). This proposal enables the EU to better grasp the potential of health data for research and innovation on new preventive strategies, as well as on diagnosis and treatment of diseases to improve health outcomes.
Vereniging Innovatieve Geneesmiddelen · filed 6 Jan 2021 · source
Pharmaceutical companies are committed to develop solutions for unmet needs and to ensure available treatments reach all patients in Europe. Patients with rare diseases and children have benefited greatly from the progress which has been realised with the OMP Regulations.
Farmaindustria · filed 6 Jan 2021 · source
FARMAINDUSTRIA RESPONSE TO THE EC PRELIMINARY IMPACT ASSESSMENT OF THE ORPHAN AND PAEDIATRIC REGULATIONS Farmaindustria, which represents the innovative pharmaceutical industry in Spain, is committed to combating uncovered diseases by promoting research into new drugs and helping to ensure patients’ access to new treatments.
Filed in Spanish · English published by the European Commission
Vereniging Innovatieve Geneesmiddelen · filed 29 Apr 2022 · source
Without the continuous and substantial investments in R &D, new technologies would not be developed. The (mRNA) vaccines and medicines used in the COVID pandemic would not have been there without the robust EU Intellectual Property (IE) system. IE, more specifically patents provide incentives for innovation through knowledge-sharing and in return temporary market protection to recoup (financial) investments.
Filed in Dutch · English published by the European Commission
Farmaindustria · filed 28 Jul 2023 · source
The EC proposal on the granting of compulsory licences (LO) is of great concern to FARMAINDUSTRIA by providing for the suspension of IP rights and preventing the choice of partners to voluntarily grant manufacturing licences for their products without any legal basis being observed to limit the use of this measure.
Filed in Spanish · English published by the European Commission
Farmaindustria · filed 26 Mar 2022 · source
Making new therapies available to patients is a long, complex and risky process that requires considerable investment, giving industrial protection — and the period for which it is effective — a key role in embarking on this process.
Filed in Spanish · English published by the European Commission
Vereniging Innovatieve Geneesmiddelen · filed 4 Apr 2022 · source
The development and marketing of new medicines requires time and investment in research, the outcome of which is uncertain: many developments do not lead to a useful medicine. There is no doubt that a well-functioning IP system is indispensable for a good innovation and investment environment.
Filed in Dutch · English published by the European Commission
Farmaindustria · filed 18 Sept 2023 · source
Farmaindustria, as the representative of the innovative pharmaceutical industry established in Spain, welcomes the proposed revision of the SPC Regulation of, given its objective of creating a harmonised and centralised approach to the application, evaluation and granting of SPC for both classical European and unitary patents (UPs), providing a clearer and more efficient framework for industrial property in the EU…
Filed in Spanish · English published by the European Commission
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.